Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin

(2013) S. C. Gordon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study

(2013) M. Vera-Llonch et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C

(2013) Pamela S. Belperio et al.   Clinical Gastroenterology and Hepatology

Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies

(2013) Jianmeng Chen et al.   GASTROENTEROLOGY

The high comorbidity burden of the hepatitis C virus infected population in the United States

(2012) Karly S Louie et al.   BMC INFECTIOUS DISEASES

Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?

(2012) J. A. Holmes et al.   JOURNAL OF VIRAL HEPATITIS

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care

(2012) Brian L Pearlman   LANCET INFECTIOUS DISEASES

A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C

(2011) Lisa I. Backus et al.   Clinical Gastroenterology and Hepatology

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still Pending

(2011) Jean–Michel Pawlotsky   GASTROENTEROLOGY

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

Gaps in the achievement of effectiveness of HCV treatment in national VA practice

(2011) Jennifer R. Kramer et al.   JOURNAL OF HEPATOLOGY

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis

(2010) Zhong-Hua Lin et al.   HEPATOLOGY

Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV‐Infected and HIV‐Uninfected Patients

(2009) José Medrano et al.   CLINICAL INFECTIOUS DISEASES

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin

(2009) Michelle Martinot-Peignoux et al.   HEPATOLOGY

Clinical Case Registries: Simultaneous Local and National Disease Registries for Population Quality Management

(2009) L. I. Backus et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

The performance of different propensity-score methods for estimating relative risks

(2008) Peter C. Austin   JOURNAL OF CLINICAL EPIDEMIOLOGY